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Abstract
Purpose Peripartum hemorrhage (PPH) remains one of the main causes of maternal mortality worldwide. Treatment includes 
administration of packed red blood cells (RBC) in severe cases and patient blood management (PBM) may reduce it sig-
nificantly. In our study, we wanted to retrospectively assess red blood cell administration in PPH to evaluate the impact of 
PBM in Switzerland.
Methods Using data from the Swiss obstetric hospital registry (Arbeitsgemeinschaft Schweizer Frauenkliniken, ASF), we 
included patients with deliveries from 1998 to 2016. We examined available obstetric data as well as blood loss and RBC 
administration in the acute and subacute peripartal phase. We categorized data into two time intervals: 1998–2011 and 
2012–2016, as new PPH guidelines in Switzerland were established in 2012.
Results PPH incidence increased between 1998 and 2016 significantly. The number of vaginal instrumental deliveries and 
cesarean sections increased as well. Administration of three or more RBC units, as defined in the ASF registry, in the acute 
and subacute phase in Switzerland has decreased after 2012. Conversely, we saw an increase in the administration of one to 
two RBC units in the acute and subacute phase. Nevertheless, overall RBC administration has been decreasing from 1998 
to 2016.
Conclusion The increase of patients obtaining one or two units of RBC for PPH suggests that there may be a potential for 
effective implication of PBM in obstetrics. Reduction of RBC transfusion in the context of PPH may not only decrease 
maternal morbidity, but decrease economic costs as well.
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Introduction
Peripartum hemorrhage (PPH) remains one of the leading 
causes of maternal mortality worldwide, with an incidence 
of more than 15% [1, 2]. According to the World Health 
Organization (WHO), PPH is defined as a blood loss of more 
than 500 ml within 24 h after delivery [3]. In German-speak-
ing countries, including Switzerland, Germany and Austria, 
PPH is defined as a blood loss of at least 500 ml after vaginal 
delivery and of at least 1000 ml after Cesarean section (CS) 
[4].
Severe PPH usually requires the administration of red 
blood cell (RBC) transfusions. Yet, the administration of 
RBC itself has been shown to be associated with compli-
cations for the patient. Specific transfusion risks include 
transmission of infections, hemolytic transfusion reactions, 
transfusion-associated circulatory overload as well as trans-
fusion-associated acute lung injury [5, 6]. But it can also 
lead to infections, ischemic events as well as multisystem 
organ failure [7]. In addition, several studies have shown that 
there are advantages to a restrictive use of RBC transfusions, 
including better clinical outcomes for patients, decreased 
morbidity and mortality, shorter hospitalization length and 
a lower risk for admission to the intensive care unit [7, 8].
Not surprisingly, other medical professions such as 
trauma or cardiothoracic surgeons introduced guidelines 
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for restrictive RBC administration, which is part of patient 
blood management (PBM). PBM is based on three pillars, 
aiming to (1) identify and treat anemia, (2) reduce blood loss 
and (3) reduce RBC administration [7, 9]. Several studies 
have shown that successful PBM leads to a quicker patient 
recovery and fewer postoperative complications [10–13]. 
To date, only few countries have implemented strategies for 
effective patient blood management in obstetrics.
In Western Australia, the PBM program has been imple-
mented since 2008 and has shown to reduce hospital mor-
tality, average hospital length of stay and hospital-acquired 
infections by one-fourth, respectively [14]. In 2015, PBM 
was developed specifically for the obstetric clinical practice 
[15].
The most common obstetric risk factors for PPH include 
placental pathologies (including abnormally invasive pla-
centa, retrained placenta or placental abruption), previous 
PPH, high maternal parity and pre-eclampsia, but also 
anemia and antepartum hemorrhage [4, 16, 17]. A further 
categorization of PPH can be made into primary or acute 
bleeding within 24 h of delivery, and secondary or subacute, 
which is bleeding after 24 h up to 12 weeks after delivery 
[18].
While some of the risk factors for PPH can be assessed 
during pregnancy and prior to delivery, up to two-thirds of 
women with a PPH have no known risk factors [19]. How-
ever, iron deficiency anemia can be assessed easily. In Swit-
zerland, new guidelines for treating anemia in pregnancy 
were implemented in 2012 and recently updated [20]. Severe 
anemia in pregnancy is associated with fetal and maternal 
morbidities such as fetal growth restriction and preterm birth 
[21, 22]. In addition, anemia itself is a known risk factor 
for PPH.
Multiple obstetric guidelines exist for PPH management, 
while in Switzerland, Germany, and Austria an universal 
guideline for PPH treatment was introduced by obstetric 
societies [4]. One important update of those guidelines 
occurred in 2012, re-evaluating the application of conserva-
tive and surgical treatment of PPH, including RBC admin-
istration [23].
The aim of our study was to examine red blood cell trans-
fusions in Switzerland over the last 18 years, using a large 
retrospectively database. Specifically, we studied the impact 
of new PPH guidelines on the administration of RBC.
Materials and methods
This was a retrospective database study using data from the 
Swiss obstetric hospital registry (Arbeitsgemeinschaft Sch-
weizer Frauenkliniken, ASF) which is managed by Sevisa 
AG. This registry includes anonymized patient delivery and 
obstetric data from 40 obstetric hospitals, including primary, 
secondary and tertiary units, in Switzerland. Most hospitals 
included in this database are primary and secondary unit 
obstetric hospitals. Data are collected by physicians in each 
involved hospital and subsequently submitted and analyzed 
by Sevisa AG.
Patients who gave birth between January 1, 1998, and 
December 31, 2016, were included. We looked at RBC 
administration in the acute and subacute phase, blood loss, 
hemoglobin levels, potential PPH risk factors, need for post-
partum intensive care unit (ICU) hospitalization, delivery 
mode and overall obstetric data. The amount of blood loss 
was determined at the discretion of each hospital (usually 
using visual estimates, weight of pads and surgical cloths, 
and surgical containers). Regarding RBC administration, we 
looked at overall RBC administration during hospitalization, 
as well as detailed data regarding administration of one or 
two RBC unit versus more three units or more (as used in the 
ASF data registry) in the acute and subacute phase during 
hospitalization after delivery.
Data were collected using administrative data. As new 
guidelines on PPH treatment were established in 2012 (as 
described above) and expected to be implemented by partici-
pating hospitals, we categorized data into two time intervals: 
1998–2011 and 2012–2016. In addition, deliveries were cat-
egorized according to delivery mode: spontaneous vaginal 
birth, instrumental vaginal delivery and Cesarean section.
Statistical analysis
This analysis was based on annual reports from 1998 to 2016 
that contained counts of categorical variables and means 
with standard deviation (SD) of continuous variables, hence 
on aggregated data. We pooled these data to achieve sum-
mary data for the two periods 1998–2011 and 2012–2016, 
respectively. To investigate whether these periods were dif-
ferent, we calculated pooled counts and % of the categori-
cal variables per period and compared the proportions by 
calculating odds ratios with 95% confidence intervals and 
exact p values. We also calculated pooled means and SDs for 
maternal age, gestational age and neonatal weight und used 
T tests to investigate differences. To assess whether there 
was a trend with respect to the absolute number of deliv-
eries and relative number of different types of deliveries, 
we calculated Spearman’s rho with corresponding p value. 
All analyses were performed using Stata 14 (Stata Corp., 
College Station, Texas). A p value < 0.05 was considered 
significant.
Results
We included a total of 627,921 deliveries from 1998 to 2016.
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From 1998 to 2016, there was an increase in cesarean 
section as well as instrumental deliveries and a decrease in 
spontaneous vaginal delivery (Fig. 1).
From 1998 to 2011, 454,463 deliveries were included, 
while from 2012 to 2016 173,458 deliveries were included. 
Peripartal data for both time intervals are summarized in 
Table 1.
Between the two time intervals 1998–2011 and 2012—
2016, there was a significant increase in mean maternal age 
and required intensive care unit (ICU) visit, and a significant 
decrease in mean birth weight. In addition, there was an 
increase in potential risk factors for PPH, including retained 
placental products, placenta previa, uterine rupture, previ-
ous cesarean sections, multiple gestation delivery, induc-
tion of labor, prolonged labor, polyhydramnios and amniotic 
infection syndrome. Interestingly, there was no difference in 
the incidence of abnormal placentation, including placenta 
accrete, increta or percreta. There was a significant increase 
in intraoperative blood loss and RBC administration of one 
to two units in the acute phase. In the subacute phase, there 
was a significant increase RBC administration of one to two 
units as well.
In the acute phase within 24 h after delivery, there was 
a decrease in the overall administration of RBC units as 
well as administration of three or more RBC units across all 
deliveries after 2012 (Fig. 2a). Instrumental vaginal deliv-
ery seems to be associated with an increased need for RBC 
administration (Fig. 2b).
In the subacute phase, there was a decrease of overall 
RBC administration as well as administration of three RBC 
units or more (Fig. 3a). In the subacute phase, instrumental 
vaginal delivery seems to be associated with an increased 
need for RBC administration as in the acute phase (Fig. 3b).
Overall, the number of three or more RBC units admin-
istered has decreased in both acute and subacute phase after 
2012, while the number of one to two RBC units adminis-
tered in the acute or subacute phase has increased after 2012. 
In addition, as can be seen in Figs. 2a and 3a, instrumental 
delivery seems to be associated with peripartum hemorrhage 
and RBC administration in the acute and subacute phase.
Discussion
As has been previously described, there is a trend towards 
increasing PPH in the past 20 years in Switzerland, with 
an increase in vaginal instrumental deliveries and cesar-
ean sections [24]. At the same time, our study shows that 
Fig. 1  a Total number of deliveries from 1998–2016; b deliveries from 1998–2016 according to delivery mode (SVD spontaneous vaginal deliv-
ery, Instrumental VD instrumental vaginal delivery, CS Cesarean section)
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despite this increase, excessive RBC administration in the 
acute and subacute phase in Switzerland has been decreas-
ing after 2012. This is in line with the implementation of 
Swiss guidelines on PPH and anemia in pregnancy [4, 20, 
23]. Nevertheless, there was an increase in the administra-
tion of one to two RBC units. Our study has also shown 
that there has been an increase in risk factors over the 
years. However, as the majority of women have no known 
risk factors for PPH, a guideline for patient blood manage-
ment should be in place which would potentially reduce 
even low RBC administration. For example, anemia is a 
major risk factor for PPH [25]. Current Swiss guidelines 
recommend regular screening of hemoglobin levels at least 
once per trimester as well as to screen for iron levels in the 
first trimester [20]. This is one step towards an effective 
patient blood management.
Yet, recently there has been more focus on acute treat-
ment of PPH with increased early use of tranexamic acid. 
Several studies have already shown and currently further 
studies are ongoing about the effective use of tranexamic 
acid as a first-line therapy or even prophylactic use for PPH 
[17, 26–29]. Other studies have indicated that the admin-
istration of carbetocin as well as oxytocin can effectively 
prevent PPH after vaginal delivery [30, 31]. In addition, cell 
saver, which uses allogenic blood, might also benefit women 
with an increased risk for PPH [32].
Table 1  Comparison of peripartal outcome and risk factors for peripartum hemorrhage from 1998–2011 and 2012–2016 (SD standard deviation, 
ICU intensive care unit, RBC red blood cell, Hb hemoglobin)
Total N = 627,921 1998–2011 2012–2016 Odds ratio (95% CI) p value
N = 453,463 N = 173,458
Mean maternal age (years) ± SD 30.0 ± 5.0 31.0 ± 4.9 < 0.001
Mean length of stay (days) 5.4 4.6
Mean gestational age (weeks) ± SD 39 1/7 ± 18 days 39 1/7 ± 18 days < 0.001
Mean birth weight (g) ± SD 3349 ± 504 3330 ± 507 < 0.001
Required ICU visit 1194 (0.3%) 676 (0.4%) 1.48 (1.35–1.63) < 0.001
Peripartum (acute phase)
 Intraoperative blood loss 500–1000 ml 40,842 (9.0%) 22,975 (13.2%) 1.54 (1.52–1.57) < 0.001
 Intraoperative blood loss > 1000 ml 5149 (1.1%) 3716 (2.1%) 1.91 (1.83–1.99) < 0.001
Peripartum RBC units (acute)
 Intraoperative 1–2 RBC units 913 (0.2%) 444 (0.3%) 1.27 (1.13–1.43) < 0.001
 Intraoperative > 2 RBC units 730 (0.2%) 250 (0.1%) 0.90 (0.77–1.04) 0.134
 Postoperative 1–2 RBC units 880 (0.2%) 425 (0.2%) 1.26 (1.12–1.42) < 0.001
 Postoperative > 2 RBC units 558 (0.1%) 180 (0.1%) 0.84 (0.71–1.00) 0.048
Hospital stay after birth (subacute)
 Hb < 100 g/l 26,431 (5.8%) 5274 (3.0%) 0.51 (0.49–0.52) < 0.001
RBC units (subacute)
 1–2 RBC units 1871 (0.4%) 953 (0.5%) 1.33 (1.23–1.44) < 0.001
 3 RBC units or more 1184 (0.3%) 400 (0.2%) 0.88 (0.79–0.99) 0.033
Possible risk factors
 Retained placental products 8744 (1.9%) 4014 (2.3%) 1.20 (1.16–1.25) < 0.001
 Placenta previa 1275 (0.3%) 654 (0.4%) 1.34 (1.22–1.48) < 0.001
 Uterine rupture 129 (0.0%) 84 (0.0%) 1.70 (1.28–2.26) < 0.001
 Previous Cesarean section 47,646 (10.5%) 24,409 (14.1%) 1.39 (1.37–1.42) < 0.001
 Multiple gestation delivery 6208 (1.4%) 3100 (1.8%) 1.31 (1.25–1.37) < 0.001
 Induction of labor 91,335 (20.1%) 36,864 (21.3%) 1.07 (1.06–1.08) < 0.001
 Prolonged labor 27,181 (6.0%) 10,891 (6.3%) 1.05 (1.03–1.08) < 0.001
 Polyhydramnios 2689 (0.6%) 1698 (1.0%) 1.66 (1.56–1.76) < 0.001
 Amniotic infection syndrome 1026 (0.2%) 521 (0.3%) 1.33 (1.19–1.48) < 0.001
 Primary uterine inertia 135,248 (29.8%) 46,106 (26.6%) 0.85 (0.84–0.86) < 0.001
 Placenta accreta/increta/percreta 1558 (0.3%) 593 (0.3%) 1.00 (0.90–1.10) 0.942
 Placental abruption 1315 (0.3%) 464 (0.3%) 0.92 (0.83–1.03) 0.137
 Pre-eclampsia 5673 (1.3%) 2310 (1.3%) 1.07 (1.01–1.12) 0.011
 Low-lying placenta 1635 (0.4%) 648 (0.4%) 1.04 (0.94–1.14) 0.439
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The strength of our study is its large sample size, the large 
time interval of 18 years and the inclusion of 40 hospitals. 
One weakness of our study is its retrospective character; 
however, due to the large sample size possibly misrecorded 
data should be largely counterbalanced. In addition, the 
two time intervals we chose were not equal in length, the 
interval from 2012 to 2016 only encompassing five years. 
Furthermore, as data for the registry is usually collected 
before placental histology becomes available, this might 
have been insufficiently recorded on data sheets. In addi-
tion, we refrained from calculating a multivariate analysis to 
investigate possible interactions of risk factors based on our 
aggregated data as results would not be interpretable because 
of associations between variables due to ecological fallacy.
Overall, our study shows that there is still a need for 
providing and optimizing PBM in obstetrics. Common 
guidelines need to be established to effectively prevent 
PPH in obstetrics. This might include a standardized 
questionnaire for PPH risk factors in a prenatal screening, 
autologous transfusion and, as already mentioned, prophy-
lactic administration of tranexamic acid. PBM is profitable 
from an economic point of view as well. It is associated 
with lower hospitalization costs, lower transfusion costs 
as well as lower in-patient costs.
Currently, PBM in obstetrics and its impact on mater-
nal and perinatal morbidity and mortality is understud-
ied. Furthermore, awareness of PBM in obstetrical units is 
low, suggesting a great potential for improving the grade 
of implementation of PBM with a beneficial medical and 
economic impact.
Fig. 2  a RBC administration in the acute phase from 1998–2016 
across all deliveries; b overall RBC administration in the acute phase 
from 1998–2016 across individual delivery modes (RBC red blood 
cell, SVD spontaneous vaginal delivery, Instrumental VD instrumen-
tal vaginal delivery, CS Cesarean section)
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